Seattle-Area Longevity Biomedical to Go Public via SPAC in Q2 2023, Raising $30M with $236M Valuation

Longevity Biomedical, formed by merging Seattle-area startups Cerevast Medical, NovoKera, and Aegeria Soft Tissue, plans to go public via a SPAC merger expected to close in Q2 2023, raising at least $30 million. The combined company targets healthspan extension with treatments for stroke, blindness, and soft-tissue reconstruction, and is valued at $236.2 million.